A carregar...
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future tri...
Na minha lista:
| Publicado no: | Genome Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436227/ https://ncbi.nlm.nih.gov/pubmed/30914057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-019-0631-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|